We further analyzed published clinical data39 (GSE78220) and revealed that GM1 was highly expressed among non-responding patients relative to responding pretreatment patients (Fig. 6C), and melanoma patients with high GM1 expression also had poor overall survival to anti-PD-1 therapy (Fig. 6D). The gene discussed is PDCD1; the disease is melanoma.